Ambit Biosciences Corporation announced today that multiple presentations from the Phase 2 ACE study of quizartinib , a FLT3 inhibitor, were presented at the Annual Meeting of the American Society of Clinical Oncology.
http://www.drugs.com/clinical_trials/ambit-announces-presentation-results-phase-2-ace-study-quizartinib-15675.html?
http://www.drugs.com/clinical_trials/ambit-announces-presentation-results-phase-2-ace-study-quizartinib-15675.html?
No comments:
Post a Comment